A PHASE 1, OPEN LABEL, SINGLE SEQUENCE, PHARMACOKINETIC STUDY OF BBP01 (EPINEPHRINE) INTRANASAL POWDER WITH AND WITHOUT NASAL ALLERGEN CHALLENGE VERSUS INTRAMUSCULAR AUTOINJECTOR EPINEPHRINE IN SUBJECTS WITH ALLERGIC RHINITIS

Registry ID

BBP01-CLN-102

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

BELHAVEN BIOPHARMA, INC.

Start date

2024-12-20

Completion date

2025-03-03

Last update

2024-12-20

Conditions

• ALLERGIES

Related clinical trials

• AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED REMIBRUTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH REMIBRUTINIB
• A PHASE 1B, OPEN-LABEL, EXPLORATORY STUDY EVALUATING THE EFFECTS OF INHALED EPINEPHRINE IN INDIVIDUALS EXPERIENCING SYSTEMIC ALLERGIC REACTIONS DURING ALLERGY TESTING, IMMUNOTHERAPY OR ORAL CHALLENGES
• PREMED-F1: FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE USE OF CETIRIZINE AS A REPLACEMENT FOR DYPHENHYDRAMINE TO PREVENT REACTIONS LINKED TO PACLITAXEL PERFUSION

View on source registry